{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-23-000037","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.600401+00:00","generated_at":"2026-06-14T10:53:13.626731+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biohaven submits NDA for troriluzole in SCA3; updates on Kv7, TYK2/JAK1, and SMA pipeline","bullets":["Submitted NDA to FDA for troriluzole in SCA3, an ultra-rare disease affecting ~10,600 people in NA, EU, Japan.","Phase 1 safety data for BHV-7000 (Kv7.2/3 activator) validates differentiated profile; pivotal studies in focal epilepsy and bipolar disorder planned in 2H2023.","Initiated Phase 1 study for BHV-8000 (brain-penetrant TYK2/JAK1 inhibitor); Phase 2 in Parkinson's expected next year.","Global Phase 3 trial of taldefgrobep alfa in SMA enrollment of ~225 patients expected to complete in 2023.","IND for novel IgG degrader BHV-1300 on track for submission in 2023; multiple new INDs planned within next year."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-23-000037","json":"https://secwatch.observer/filing/0001935979-23-000037.json","markdown":"https://secwatch.observer/filing/0001935979-23-000037.md","text":"https://secwatch.observer/filing/0001935979-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000037/0001935979-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000037/bhvn-20230531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:53:13.626731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}